Healthcare Stocks Technical Reports -- Skyline Medical; Baxter; Becton, Dickinson; and Hill-Rom

Sep 09, 2016, 07:40 ET from Chelmsford Park SA

NEW YORK, September 9, 2016 /PRNewswire/ --

Investor confidence in the global Medical Instruments and Supplies space remains strong as the industry continues to impress with increasing number of deals. Ahead of today's trading session, has lined up four potential prospects for review: Skyline Medical Inc. (NASDAQ: SKLN), Baxter International Inc. (NYSE: BAX), Becton, Dickinson and Co. (NYSE: BDX), and Hill-Rom Holdings Inc. (NYSE: HRC). Download the free research reports on these stocks today:

Skyline Medical  

On Thursday, shares in Eagan, Minnesota-based Skyline Medical Inc. recorded a trading volume of 59.00 million shares, which was above their three months average volume of 10.04 million shares. The stock ended the session 7.32% lower at $0.18. The Company's shares have surged 50.41% in the last one month and 41.15% over the previous three months. The stock is trading 40.23% above its 50-day moving average. Moreover, shares of Skyline Medical, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, have a Relative Strength Index (RSI) of 63.42.

On August 30th, 2016, Skyline Medical announced the signing of a letter of intent to form a joint venture with Electronic On-Ramp, Inc. (EOR), a Native American Indian, (8a) certified Small Disadvantaged Business owned by a Service Disabled Veteran. EOR's Partner contracts with the U.S. National Institutes of Health (NIH) and Department of Defense are expected to provide Skyline Medical with access to bid on procurement contracts for up to $550 million or more in federal funds budgeted for health, security, life safety systems support, humanitarian assistance and disaster preparedness. See our free and comprehensive research report on SKLN at:

Baxter Intl. 

Deerfield, Illinois headquartered Baxter International Inc.'s stock closed the day 0.37% higher at $46.07. A total volume of 5.15 million shares was traded, which was higher than their three months average volume of 3.86 million shares. The Company's shares have advanced 3.24% in the previous three months and 21.81% on an YTD basis. The stock is trading 10.24% above its 200-day moving average. Additionally, shares of Baxter International, which provides a portfolio of renal and hospital products, have an RSI of 35.22.

On August 25th, 2016, Baxter International and Satellite Healthcare, the sixth largest provider of patient-centered dialysis and kidney disease services in the U.S., announced an agreement to provide patients with the latest advancements in peritoneal dialysis, hemodialysis and continuous renal replacement therapy. Under the four-year agreement, Satellite Healthcare plans to offer AMIA Automated Peritoneal Dialysis (APD) system with SHARESOURCE to peritoneal dialysis (PD) patients, and integrate REVACLEAR into its high-flux hemodialysis therapy offering at its 80 Satellite Dialysis and Satellite WellBound home dialysis centers that serve more than 7,000 patients nationwide. Details of the agreement were not disclosed. BAX free research report PDF is just a click away at:

Becton, Dickinson  

Shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. recorded a trading volume of 743,513 shares. The stock ended yesterday's trading session 0.62% lower at $176.65. The Company's shares have advanced 1.81% in the past month, 4.16% in the previous three months, and 16.03% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.66% and 11.73%, respectively. Furthermore, shares of Becton, Dickinson and Co., which develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide, have an RSI of 56.24.

On September 06th, 2016, the company announced that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV Assay, its human papillomavirus (HPV) test. The company's Onclarity HPV Assay PMA is supported by data collected during a two-year, prospective, multi-center clinical trial with more than 33,000 women enrolled, one of the largest clinical trials ever conducted by the company.  Sign up for your complimentary report on BDX at:

Hill-Rom Holdings  

Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock finished Thursday's session 0.67% lower at $59.58 with a total volume of 344,145 shares traded. The Company's shares have advanced 4.09% in the last one month, 16.32% over the previous three months, and 24.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.96% and 18.80%, respectively. Additionally, shares of Hill-Rom Holdings, which operates as a medical technology company worldwide, have an RSI of 67.57.

On August 4th, 2016, Hill-Rom reported earnings of $0.68 per diluted share, an increase of 106%, compared to $0.33 per diluted share in the prior-year period. Hill-Rom's Q3 worldwide revenue was $655 million, a 38% growth compared to the prior-year period. Register for free on and download the latest research report on HRC at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA